Clinical trials: CYP2D6 Polymorphism
Post-cesarean Pain, CYP2D6 Polymorphism
The Impact of CYP2D6 Polymorphism on Tramadol Pharmacodynamics
CYP2D6 is an enzyme involved in the hepatic metabolism of many clinically important drugs: antiarrhythmics, antidepressants, antipsychotics, β-blockers, and analgesics such as tramadol and codeine.
- Conditions
- Post-cesarean Pain, CYP2D6 Polymorphism, Tramadol Resistance
- Trial name
- NCT06814652
- Testing
- Trodon® Hemofarm
- Where
- Iraq
- Volunteers
- 40 people
- Sponsor
- Elweyia Maternity Teaching Hospital
Depression, Psychiatric Diagnosis
Long-term Follow-up of Depressive Disorders in Psychiatric Care
The project investigates long-term prognosis and predictors of treatment outcomes for difficult-to-treat depression in patients in secondary psychiatric care.
- Conditions
- Depression, Psychiatric Diagnosis, Personality Disorders, Suicide, Attempted
- Trial name
- NCT07078227
- Testing
- No intervention is used.
- Where
- 2 sites in Sweden
- Volunteers
- 415 people
- Sponsor
- Region Skane
CYP2D6 Polymorphism
Effects of Isotretinoin on CYP2D6 Activity
Specific Aim: To investigate if isotretinoin (13-cis-retinoic acid) administration decreases CYP2D6 activity in adolescent patients.
- Trial name
- NCT03076021
- Testing
- Isotretinoin, dextromethorphan
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Washington
CYP2D6 Polymorphism
Effects of Retinoids on CYP2D6 Activity During Pregnancy
Prospective drug interaction study during pregnancy.
- Trial name
- NCT03117660
- Testing
- Vitamin A
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of Washington
Malaria, Vivax Malaria
Biomarkers of P. Vivax Relapse
Plasmodium vivax malaria is difficult to manage because even after taking medicine that kills the infection in the blood, it can continue to hide quietly in the liver, later re-emerging into the blood and causing another episode…
- Conditions
- Malaria, Vivax Malaria, Relapse, CYP2D6 Polymorphism
- Trial name
- NCT04228315
- Testing
- Primaquine
- Where
- Thailand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Armed Forces Research Institute of Medical Sciences, Thailand
Pain, CYP2D6 Polymorphism
Precision Medicine Guided Treatment for Cancer Pain
Pain is one of the most burdensome symptoms associated with cancer and its treatment, and opioids are the cornerstone of clinical pain management in cancer patients.
- Trial name
- NCT02664350
- Testing
- CYP2D6, Brief Pain Inventory-Short Form (BPI-SF), M.D. Anderson Symptom Inventory (MDASI)
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of Florida
CYP2D6 Polymorphism
A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）
This is a multicenter, randomized, open-label, parallel, active-controlled superiority clinical study conducted in early premenopausal estrogen-receptor positive breast cancer patients with CYP2D6*10 mutations.
- Trial name
- STEP (NCT03137368)
- Testing
- Exemestane Tablets, ovarian function suppression/ablation, CYP2D6*10 gene test
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Analgesia, CYP2D6 Polymorphism
Cytochrome P450's Pharmacogenomics in Chronic Pain Patients
The use of titrated drugs is at the base of a successful antalgic treatment in order to provide both an adequate relief and a satisfactory tolerability profile.
- Conditions
- Analgesia, CYP2D6 Polymorphism, Opioid Use, Chronic Pain
- Trial name
- FACIDOCRO (NCT03411759)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Bologna
Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM
This randomized controlled trial will evaluate whether the use of pharmacogenetic testing through a Medication Therapy Management (MTM) program has a beneficial impact on drug therapy problems.
- Conditions
- Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant
- Trial name
- NCT02428660
- Testing
- Pharmacogenetic testing, Software-based drug & gene interaction risk analysis, MTM
- Where
- United States
- Volunteers
- 341 people
- Sponsor
- Genelex Corporation
Breast Cancer, CYP2D6 Polymorphism
Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms
Tamoxifen is an important drug for the treatment of breast cancer. Used adjuvantly after operation in early breast cancer, tamoxifen reduces annual recurrence rate by half and cancer death by one third.
- Trial name
- TADE (NCT01075802)
- Testing
- Tamoxifen
- Where
- 2 sites in Australia
- Volunteers
- 121 people
- Sponsor
- Western Sydney Local Health District